Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.1 As of April 14, 2020, there have been more than 1.5 million reported cases and 124 000 deaths in more than 200 countries. A recent open-label nonrandomized French study reporte that addition of azithromycin to hydroxychloroquine in 6 patients resulted in numerically superior viral clearance (6/6, 100%) compared with hydroxychloroquine monotherapy (8/14, 57%) or control (2/16, 12.5%). Azithromycin alone has never been tested, whereas azithromycin has immunomodulating and anti-inflammatory properties that could theoretically prevent or limit secondary worsening. Our hypothesis is that azithromycin combined with amoxicillin/clavulanate will be superior to amoxicillin/clavulanate alone to obtain viral clearance at Day 6 in COVID-19 patients with pneumonia and hospitalized in a non-intensive care unit ward.
Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 6Description: Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample
Measure: Rate of positive SARS-CoV-2 RT-PCR Time: Day 10Description: Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 score. Scale ranging from 0 to 8 (0:unifected; 8:dead)
Measure: Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19 Time: day 6, day 10, and day 30Description: Total duration of antibiotic treatment during the 30 days following inclusion
Measure: Total duration of antibiotic treatment during the 30 days following inclusion Time: 30 daysDescription: Number of all-cause mortality during the 30 days following inclusion
Measure: Number of all-cause mortality during the 30 days following inclusion Time: 30 daysDescription: Number of in-hospital mortality during the 30 days following inclusion
Measure: Number of in-hospital mortality during the 30 days following inclusion Time: 30 daysDescription: Number of patients transferred to intensive care unit during the 30-day follow-up
Measure: Number of patients transferred to intensive care unit during the 30-day follow-up Time: 30 daysDescription: Number of days without mechanical ventilation during the 30 days following inclusion
Measure: Number of days without mechanical ventilation during the 30 days following inclusion Time: 30 daysDescription: adverse events attributable to antibiotic treatment during the 30 days following inclusion
Measure: adverse events attributable to antibiotic treatment during the 30 days following inclusion Time: 30 daysDescription: Hospital length of stay during the 30 days following inclusion
Measure: Hospital length of stay during the 30 days following inclusion Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports